TW200621266A - Methods of treating proliferative skin diseases using carbazole derivatives - Google Patents

Methods of treating proliferative skin diseases using carbazole derivatives

Info

Publication number
TW200621266A
TW200621266A TW094131097A TW94131097A TW200621266A TW 200621266 A TW200621266 A TW 200621266A TW 094131097 A TW094131097 A TW 094131097A TW 94131097 A TW94131097 A TW 94131097A TW 200621266 A TW200621266 A TW 200621266A
Authority
TW
Taiwan
Prior art keywords
skin diseases
methods
proliferative skin
carbazole derivatives
treating proliferative
Prior art date
Application number
TW094131097A
Other languages
English (en)
Chinese (zh)
Inventor
Samuel R Denmeade
Robert L Hudkins
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of TW200621266A publication Critical patent/TW200621266A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW094131097A 2004-09-10 2005-09-09 Methods of treating proliferative skin diseases using carbazole derivatives TW200621266A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60920304P 2004-09-10 2004-09-10
US11/222,409 US20060058250A1 (en) 2004-09-10 2005-09-08 Methods of treating proliferative skin diseases using carbazole derivatives

Publications (1)

Publication Number Publication Date
TW200621266A true TW200621266A (en) 2006-07-01

Family

ID=36034857

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094131097A TW200621266A (en) 2004-09-10 2005-09-09 Methods of treating proliferative skin diseases using carbazole derivatives

Country Status (14)

Country Link
US (1) US20060058250A1 (https=)
EP (1) EP1786418A1 (https=)
JP (1) JP2008512497A (https=)
KR (1) KR20070113186A (https=)
AR (1) AR050930A1 (https=)
AU (1) AU2005285007A1 (https=)
BR (1) BRPI0515115A (https=)
CA (1) CA2577024A1 (https=)
IL (1) IL181003A0 (https=)
MX (1) MX2007002532A (https=)
MY (1) MY156431A (https=)
NO (1) NO20071052L (https=)
TW (1) TW200621266A (https=)
WO (1) WO2006031772A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
DK1044203T3 (da) * 1997-12-31 2003-07-14 Cephalon Inc 3'-epimere K-252a-derivater
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
EP1309721A2 (en) * 2000-08-11 2003-05-14 Cephalon, Inc. Modulating multiple lineage kinase proteins
US6667173B2 (en) * 2000-12-01 2003-12-23 The Schepens Eye Research Institute Nucleic acids encoding platelet derived growth factor-alpha receptors
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles

Also Published As

Publication number Publication date
JP2008512497A (ja) 2008-04-24
BRPI0515115A (pt) 2008-07-01
MX2007002532A (es) 2007-05-09
EP1786418A1 (en) 2007-05-23
AR050930A1 (es) 2006-12-06
IL181003A0 (en) 2007-07-04
AU2005285007A1 (en) 2006-03-23
KR20070113186A (ko) 2007-11-28
WO2006031772A1 (en) 2006-03-23
US20060058250A1 (en) 2006-03-16
NO20071052L (no) 2007-04-03
MY156431A (en) 2016-02-26
CA2577024A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
UA94097C2 (ru) Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
MY169308A (en) Treatment of tnf? related disorders
DE60329001D1 (en) 8-hydroxychinolinderivate
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
EP1515724A4 (en) MITOTIC KINESINE HEMMER
IL174210A0 (en) 1,4 disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
MX346186B (es) Inhibidores de proteina cinasas.
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
WO2008031551A3 (en) Non-neuroendocrine cancer therapy
MX374396B (es) Rocio de fentanilo sublingual.
MX2012002758A (es) Pirazinil-piridinas utiles para el tratamiento de enfermedades proliferativas.
TN2011000227A1 (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
MXPA05004621A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes.
IL162384A0 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
MX394860B (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
TW200631606A (en) Organic compounds
TW200612922A (en) Inhibitors of hsp90
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.